PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (“XGen”), a Nevis Island limited liability company.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex ANX) reports that the Company’s Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday September 14, 2010 at 11:40 a.m. Eastern time, in the Hubbard Salon at the New York Palace Hotel in New York.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals website. An archived presentation will be available on the website for 30 days.
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.
ADVENTRX Pharmaceuticals’ lead product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine, and ANX-514 (docetaxel lyophilized emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs.
XOMA Ltd. (Nasdaq:XOMAD), a leader in the discovery and development of therapeutic antibodies, reports that NASDAQ has notified the Company that it regained compliance with the minimum $1.00 per share bid price requirement for continued listing. Accordingly, the Company will continue to be listed on The NASDAQ Global Market.
Following a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”), the Panel determined to continue the Company’s listing subject to the condition that, on or before September 13, 2010, the Company evidence a closing bid price of $1.00 per share or more for at least the ten prior consecutive trading days. The Company’s closing bid price exceeded the $1.00 per share threshold on each of the 10 consecutive trading days from August 18, 2010 through August 31, 2010. Accordingly, the Company satisfied the Panel’s condition and the delisting proceeding is now closed.
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government.
No comments:
Post a Comment